Gateway 2011: Jost Chemical Co - Pharmaceutical Technology

Latest Issue
PharmTech

Latest Issue
PharmTech Europe

Gateway 2011: Jost Chemical Co


Your online Gateway to Jost Chemical Co. in 2011

"Quality Delivered On-Time"

8150 Lackland
St. Louis, MO   63114
Phone: +1.314.428.4300
Fax: +1.314.428.4366
www.jostchemical.com

For over 25 years Jost Chemical Co. has manufactured high purity specialty chemicals for the pharmaceutical, nutritional, food and reagent market. Jost’s St. Louis, MO site, comprised of two manufacturing buildings totaling 190,000 ft2, is FDA registered and operates under ICH Q7 bulk pharmaceutical cGMP’s. Our 250+ high purity chemical salts are manufactured to meet USP/EP/BP/JP/ACS/FCC and multi-compendia requirements and are BSE/TSE free and allergen free. By continually focusing on product quality through controlled validated processes and lot-to-lot product consistency, Jost is able to meet specific product requirements and if required can develop a DMF, ASMF and CEP. Packaging options include fiber drums, poly drums, poly pails, cartons, super sacks, etc. Custom packaging is also available. Please visit Jost’s website at www.jostchemical.com to access information on product specifications, MSDS’s and various product certifications.


Visit our Stand: Number FOD10


We look forward to meeting with you at the 2011 CPhI Exhibition in Frankfurt, Germany to discuss how Jost Chemical can assist in your drug development projects. Please contact Jeff Lenger, Director of Sales and Marketing, to arrange a meeting at CPhI. Jeff can be contacted at jeff.lenger@jostchemical.com

 

Jost Lab

New Products
and Releases
New Whitepapers

Coming soon!

Coming soon!



ADVERTISEMENT

blog comments powered by Disqus
LCGC E-mail Newsletters

Subscribe: Click to learn more about the newsletter
| Weekly
| Monthly
|Monthly
| Weekly

Survey
How does your company apply quality-by-design (QbD) principles to manufacturing processes?
To all processes for both new and legacy products
To all process for new products only
To select process for new products only
To select processes for both new and legacy products
Do not use QbD
To all processes for both new and legacy products
22%
To all process for new products only
12%
To select process for new products only
22%
To select processes for both new and legacy products
22%
Do not use QbD
24%
View Results
UPCOMING CONFERENCES

Programs for Investigational and Pre-Launch Drugs
Philadelphia, PA
July 17-18, 2013
Request Brochure

Strategic Pipeline Planning & Portfolio Valuation
Philadelphia, PA
August 13-14, 2013
Request Brochure

MES 2013 - Forum on Manufacturing Execution Systems
Philadelphia, PA
August 14-15, 2013
Request Brochure

Mobile Innovation for the Life Sciences Industry
Philadelphia, PA
August 20-21, 2013
Request Brochure

See All Conferences >>

Eric Langer Outsourcing Outlook Eric LangerOutsourcing's Modest Role as a Cost-Containment Strategy
Patricia Van Arnum Ingredients Insider Patricia Van ArnumIntellectual Property Battles in Solid-State Chemistry
Nathan Jessop Industry Insider Nathan Jessop Campaign Against Counterfeit Drugs Continues
Lynn Torbeck Statistical Solutions Lynn D. TorbeckCompositing Samples and the Risk to Product Quality
 More
Inadequate Access to Medicines Puts EU at Risk
FDA Offers Insight on QbD for Modified-Release Products
Global Biosimilars Market to Reach $2.445 Billion in 2013
Adapting to Change
AstraZeneca and Exco InTouch Collaborate to Augment Current COPD Pathways
FindPharma Custom Search

Click here